A Drug with Two Prices
After 20 years, the monopoly for Abbvie’s Humira (adalimumab) has ended with the recent entry of Amgen’s biosimilar Amjevita. However, Amgen’s dual pricing strategy for its product has been raising some eyebrows.
- PBM Concerns Induce Surprising Bipartisanship
- MGA’s Latest Work Examining Digital Health Tools
- ‘The Price of Business’: Discussing the Debt Crisis
- A More Affordable Future Through Competition
- A Drug with Two Prices
- ‘The Price of Business’: Discussing the Future of Working at Home
- Health Care Workforce Shortages: An Updated Look
- New MGA Analysis of the Adalimumab Biosimilars Market in the United States
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing the Recent Tax Policy Proposal
- Bipartisan Senate Bill Aims to Curb Drug Patent Abuse
